RecruitingNCT06894576
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
Sponsor
Ottawa Hospital Research Institute
Enrollment
1,000 participants
Start Date
Dec 3, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types
- Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing.
- Estimated life expectancy > 6 months
- Willingness to give an informed consent
- Age ≥ 18 years
Exclusion Criteria4
- Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis)
- Superficial vein thrombosis
- Refusal of informed consent > 72 hrs of anticoagulants
- Age < 18 years old
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06894576